Clinical Trial Update: Multiple Ascending Dose Study of BMS-929075 in Hepatitis C Virus (HCV) Infected Patients [Phase 1]

View source ↗

Summary

A Phase 1 multiple ascending dose study of BMS-929075 in patients with chronic hepatitis C has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• BMS-929075

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Chronic Hepatitis C | Phase 1 | Status: WITHDRAWN